ASTELLAS PHARMA EUROPE LTD.

Astellas, one of Japan's largest life sciences companies, announced a €129 million investment in its Irish operations over the next three years, focusing on development, sustainability, and research initiatives.

The 15th World ADC San Diego conference (November 4-7, 2024) represents the industry's largest and most comprehensive ADC-focused forum, featuring 120+ speakers across six development tracks.

Royalty Pharma shareholders have overwhelmingly approved the acquisition of its external manager, with 99.9% voting in favor at the company's 2025 Annual General Meeting.

Dyno Therapeutics has launched three breakthrough AAV capsid vectors targeting the eye, muscle, and central nervous system, each demonstrating significant improvements over conventional AAV vectors in non-human primates.

Bayer received FDA approval for Nubeqa (darolutamide) in combination with docetaxel chemotherapy for metastatic hormone-sensitive prostate cancer, expanding beyond its initial non-metastatic indication.

The global 3D Cell Culture market is projected to reach $3.48 Billion by 2028, driven by its potential to enhance drug discovery and reduce costly attrition rates in pharmaceutical development.

• Aviceda Therapeutics has raised $207.5 million in a Series C financing round to advance its AVD-104 program for geographic atrophy (GA). • The funding will support the ongoing Phase 2b/3 trial and planned pivotal Phase 3 clinical trial of AVD-104, a novel immunomodulator. • AVD-104 targets both immune modulation and complement inhibition, showing promise in slowing GA lesion growth and preserving visual function. • The Phase 2b/3 trial data, comparing AVD-104 to avacincaptad pegol (Izervay), is expected in the second half of 2025.

The FDA has granted Priority Review to Astellas' Biologics License Application (BLA) for zolbetuximab, a Claudin 18.2-targeted monoclonal antibody.

• Pfizer has terminated its partnership with Sangamo Therapeutics for the hemophilia A gene therapy, giroctocogene fitelparvovec, despite promising Phase III trial results. • This decision by Pfizer casts doubt on the commercial viability of first-generation hemophilia A gene therapies, influenced by the slow market uptake of BioMarin's Roctavian. • Sangamo's stock plummeted by 56% following the announcement, as the company loses potential milestone payments of up to $220 million from Pfizer. • Sangamo now intends to explore all options for advancing the gene therapy, including seeking a new collaboration partner, while facing financial challenges with limited cash reserves.

A meta-analysis of seven RCTs demonstrates that fezolinetant and elinzanetant significantly reduce the frequency of vasomotor symptoms in menopausal women.